SMN2 and proximal spinal muscular atrophy: Zhang et al., introduced an artificial mismatch into the crRNA in their assay to avoid SMN2 cross-reaction, and the results showed a 7.41-fold fluorescence difference between samples from non-SMA individuals and SMA patients, which was higher than the difference measured using the wild-type crRNA (2.26-fold) [20].